Read more
Emerging illicit drugs pose a significant clinical challenge. This handbook offers an engaging, concise guide to managing these challenges.
List of contents
Part I: 1. Introduction 2. What are NPS and Club Drugs and why are they important; 3. A brief history of NPS production and distribution; 4. Drugs classification framework for Club Drugs and NPS; 5. Clinical challenge of Club Drugs and NPS; Part II. Stimulant Drugs; 6. Stimulant drugs: introduction; 7. Stimulant drugs: cocaine; 8. Stimulant drugs: amphetamine-type; 9. Stimulant drugs: methamphetamine; 10. Stimulant drugs: MDMA; 11. Stimulant drugs: synthetic cathinones; Part III. Depressant Drugs; 12. Depressant drugs: introduction; 13. Depressant drugs: GHB/GBL; 14. Depressant drugs: Fentanyl, Fentanyl analogues and other opioid NPS; 15. Depressant drugs: Benzodiazepine NPS; 16. Depressant drugs: Ketamine and its anaologues; Part IV. Synthetic Cannabinoid Receptor Agonsits; 17. Synthetic cannabinoid receptor agonists (SCRAs); Part V. Hallucinogens; 18. Hallucinogens; Part VI. Concluding Remarks and References; 19. Concluding Remarks; 20. References.
About the author
Owen Bowden-Jones is Consultant in Addiction Psychiatry and Founder of the CNWL Club Drug Clinic, London, and Honorary Professor at University College London. He is Chair of the Advisory Council on the Misuse of Drugs and National Clinical Adviser to the Alcohol, Drugs and Tobacco division at Public Health England.
Summary
Emerging illicit drugs pose a significant clinical challenge. This handbook offers an engaging, concise guide to managing these challenges.
